Skip to main content
SpringerLink
Log in

Neuromuskuläre Erkrankungen

  • Chapter
NeuroIntensiv

  • 3817 Accesses

Zusammenfassung

Das Guillain-Barré-Syndrom (GBS) ist nach dem fast völligen Verschwinden der Poliomyelitis die häufigste Ursache akuter peripherer Lähmungen in der westlichen Welt geworden. Die jährliche Inzidenz liegt zwischen 1 und 2 Fällen pro 100.000 Einwohner mit leichter Bevorzugung des männlichen Geschlechts [28].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Zu 37.1

  1. Bernsen RA, deJager AE, Kuijer W, et al. (2010) Psychosocial dysfunction in the first year after Guillain-Barré syndrome. Muscle Nerve 41:533–539

    PubMed  Google Scholar 

  2. Buchwald B, Ahangari R, Weishaupt A, et al. (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain- Barre syndrome. Ann Neurol 51:673–680

    PubMed  CAS  Google Scholar 

  3. Dionne A, Nicolle MW, Hahn AF (2010) Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41:202–207

    PubMed  Google Scholar 

  4. Dutch Guillain-Barre Study Group (1994) Treatment of Guillain- Barre-Syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752

    Google Scholar 

  5. Farcas P, Avnun L, Frisher S, et al. (1997) Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain- Barre syndrome. Lancet 350:1747

    PubMed  CAS  Google Scholar 

  6. Feasby TE, Gilbert JJ, Brown WF, et al. (1986) An acute axonal form of Guillain-Barre polyneuropathy. Brain 109:1115–1126

    PubMed  Google Scholar 

  7. French cooperative group on plasma exchange in Guillain-Barre syndrome (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 22:753–761

    Google Scholar 

  8. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann. Neurol 41:298–306

    Google Scholar 

  9. Gold R, Dalakas MC, Toyka KV (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2:22–32

    PubMed  CAS  Google Scholar 

  10. Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology – therapeutic considerations and practical issues. Nat Clin Prac Neurol 3:36–44

    CAS  Google Scholar 

  11. Guillain-Barre Syndrome Steroid Trial Group (1993) Doubleblind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341:586–590

    Google Scholar 

  12. Hadden RD, Cornblath DR, Hughes RA, et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780–788

    PubMed  CAS  Google Scholar 

  13. Heritier F, Rahm F, Pasche P, et al. (1994) Sniffnasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med 150:1678–1683

    PubMed  CAS  Google Scholar 

  14. Hilz MJ, Dütsch M (2005) Methoden zur quantitativen Evaluation des autonomen Nervensystems. Nervenarzt 76:767–778

    PubMed  Google Scholar 

  15. Ho TW, Hsieh ST, Nachamkin I, et al. (1997) Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection [see comments]. Neurology 48:717–724

    PubMed  CAS  Google Scholar 

  16. Hughes RAC, Swan AV, Cornblath DR, et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349:225–230

    Google Scholar 

  17. Hughes RAC, Cornblath DR (2005) Guillain-Barré syndrome Lancet 366:1653–1666

    CAS  Google Scholar 

  18. Kaida K, Kasunoki S (2010) Antibodies to gangliosides andd gangliosid complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol 233:5–12

    Google Scholar 

  19. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. (2009) Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66:597–603

    PubMed  CAS  Google Scholar 

  20. Levine S, Nguyen T, Taylor N, et al (2008) Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. New Engl J Med 358:1327–1328

    PubMed  CAS  Google Scholar 

  21. McKhann GM, Cornblath DR, Griffin JW, et al. (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 33:333–342

    PubMed  CAS  Google Scholar 

  22. Merkies IS, Schmitz PI, Samijn JP, et al. (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53:1648–1654

    PubMed  CAS  Google Scholar 

  23. Mori K, Hattori N, Sugiura M, et al. (2002) Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58:979–982

    PubMed  CAS  Google Scholar 

  24. Mukerji S, Aloka F, Farooq MU, et al (2009) Cardiovascular complications of the Guillain-Barré syndrome. Am J Cardiol 104:1452–1455

    PubMed  Google Scholar 

  25. Müllges W, Toyka KV (1997) Akute Muskelschwäche – Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 34:110–123

    Google Scholar 

  26. Müllges W, Stoll G (2009) Intensivmedizinische Probleme bei neuromuskulärern Krankheiten. Intensivmed up2date 5:209–228

    Google Scholar 

  27. Needham DM (2008) Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA 300:1685–1690

    PubMed  CAS  Google Scholar 

  28. Nelson L, Gormley R, Riddle MS, et al. (2009) The epidemiology of Guillain-Barré syndrome in US military personnel. BMC Res Notes 2:171–175

    PubMed  Google Scholar 

  29. PSGBS study group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230

    Google Scholar 

  30. Raphael JC, Chevret S, Harboun M, et al. (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238

    PubMed  CAS  Google Scholar 

  31. Van Der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326:1123–1129

    PubMed  Google Scholar 

  32. Van Koningsveld R, Schmitz PIM, Van Der Meche FGA, et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192–196

    PubMed  Google Scholar 

  33. Vucic S, Kieman MC, Cornblath DR 2009) Guillain-Barré syndrome: an update. J Clin Neurosci 16:733–741

    PubMed  Google Scholar 

  34. Weiß H, Lauter V, Müllges W, et al. (2002) Psychotic symptoms and emotional distress in patients suffering from acute Guillain- Barré syndrome. Eur Neurol 47:74–78

    PubMed  Google Scholar 

  35. Yang KL, Tobin MJ (1991) A prospective study of indexes predicting the outcome of trial of weaning from mechanical ventilation. N Engl J Med 324:1445–1450

    PubMed  CAS  Google Scholar 

  36. Yuki N (2007) Ganglioside mimicry and peripheral nerve disease. MuscleNerve 35:691–711

    CAS  Google Scholar 

Zu 37.2

  1. Alterman I, Sidi A, Azamfirei L, Copotoiu S, Ezri T (2007) Rhabdomyolysis: another complication after prolonged surgery. Journal of Clinical Anesthesia 19:64–66

    PubMed  Google Scholar 

  2. Balcarek P, Frosch KH, Quintel M, Stürmer KH (2005) Systemisches Kapillarlecksyndrom als Ursache eines Kompartmentsyndroms beider Unterschenkel und eines Unterarms. Unfallchirurg 108:770–776

    PubMed  CAS  Google Scholar 

  3. Hansen HC (2003) Rhabdomyolyse. Intensivmed 40:294–300

    Google Scholar 

  4. Hensel M, Böhler K, Matrnitz R, Binder C, von Brevern M (2010) Intensivmedizinisches Management des malignen neuroleptischen Syndroms. Anästhesiol Intensivmed Notfallmed Schmerzther 45:448–455

    PubMed  Google Scholar 

  5. Klockgether T, Weller M, Haarmeir T, Kaskas B, Maier G, Dichgans J (1997) Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology 48:275–276

    PubMed  CAS  Google Scholar 

  6. Köller H, Neuhaus O, Schroeter M, Hartung HP (2005) Myopathien unter der Therapie mit Lipidsenkern. Nervenarzt 76:212–217

    PubMed  Google Scholar 

  7. Maddison P (2002) Acute rhabdomyolysis and brachial plexopathy following alcohol ingestion. Muscle Nerve 25:283–285

    PubMed  Google Scholar 

  8. Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK (1993) A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 52:387–398

    PubMed  CAS  Google Scholar 

  9. Rich MM, Teener JW, Raps EC, Schotland MD, Bird SJ (1996) Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 46:731–736

    PubMed  CAS  Google Scholar 

  10. Schwab S, Krieger D, Müllges W (Hrsg) (1999) Neurologische Intensivmedizin. Springer, Berlin

    Google Scholar 

  11. Winkler G, Beese M (1998) Rhabdomyolysen. In: Beese M, Winkler G (Hrsg) MRT der Muskulatur. Thieme, Stuttgart, S 247–256

    Google Scholar 

  12. Zaccheo MM, Bucher DH (2008) Propofol Infusion Syndrome. Crit Care Nurse 28:18–27

    PubMed  Google Scholar 

Zu 37.3

  1. Anetseder M, Hager M, Müller CR, Roewer N (2002) Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359:1579–1580

    PubMed  Google Scholar 

  2. Anetseder M, Hartung E, Klepper S, Reichmann H (1994) Gasoline vapors induce severe rhabdomyolysis. Neurology 44:2393–2395

    PubMed  CAS  Google Scholar 

  3. Anetseder M, Roewer N (2008) Maligne Hyperthermie. In: Rossaint R, Werner C, Zwissler B (Hrsg) Die Anästhesiologie, S 1314–1323

    Google Scholar 

  4. Baur CP, Schara U, Schlecht R, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 2: Specific disorders. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:125–137

    CAS  Google Scholar 

  5. Baur CP, Schlecht R, Jurkat-Rott K, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 1: Introduction. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:77–83

    CAS  Google Scholar 

  6. Beschluss des Engeren Präsidiums der DGAI vom 11.04.2008 (2008) Empfehlung zur Therapie der malignen Hyperthermie. Anästh Intensivmed 49:483–488

    Google Scholar 

  7. Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2:45–50

    Google Scholar 

  8. Duke AM, Hopkins PM, Halsall PJ, Steele DS (2006) Mg2+ dependence of Ca2 +release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. Br J Anaesth 97:320–328

    PubMed  CAS  Google Scholar 

  9. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S (2001) B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle by ryanodine receptor activators. J Biol Chem 276:48077–82

    PubMed  CAS  Google Scholar 

  10. Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, Wappler F (2010) Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. B J Anaesth 105:417–420

    CAS  Google Scholar 

  11. Gronert GA, Antognini JF, Pessah (2000) Malignant Hyperthermia. In: Miller RD (ed) Anesthesia. Elsevier, Philadelphia, pp 1033–1052

    Google Scholar 

  12. Hüttemann K, Nowe T, Köhrmann M, Anetseder M, Schellinger PD (2009) Maligne Hyperthermie und deren Differenzialdiagnosen. Fortschr Neurol Psychiat 77:203–211

    PubMed  Google Scholar 

  13. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB (2010) Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 110:498–507

    PubMed  Google Scholar 

  14. Leong P, MacLennan DH (1998) A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor. J Biol Chem 273:7791–7794

    PubMed  CAS  Google Scholar 

  15. Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR (2008) Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology 109:825–829

    PubMed  Google Scholar 

  16. Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignanthyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60:1316–1325

    PubMed  CAS  Google Scholar 

  17. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 41:955–966

    PubMed  CAS  Google Scholar 

  18. Parnes J, Bandschapp O, Girard T (2009) The Myotonias and Susceptibility to Malignant Hyperthermia. Anesth Analg 109:1054–1064

    Google Scholar 

  19. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27:977–989

    PubMed  CAS  Google Scholar 

  20. Robinson RL, Anetseder MJ, Brancadoro V, Van Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klinger W, Kozak-Ribbens G, Krivosic R, Monnier N, Nivoche Y, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 11:342–348

    PubMed  CAS  Google Scholar 

  21. Rosenberg H (1987) Trismus is not trivial. Anesthesiology 67:453–455

    PubMed  CAS  Google Scholar 

  22. Rossaint R, Werner C, Zwissler B (2008) Die Anästhesiologie, 2. Aufl. Springer, Berlin Heidelberg New York

    Google Scholar 

  23. Rüffert H, Wehner M, Deutrich C, Olthoff D (2007) Malignant hyperthermia. The ugly. Anaesthesist 56:923–929

    PubMed  Google Scholar 

  24. Schuster F, Müller R, Hartung E, Roewer N, Anetseder M (2005) Inhibition of sarcoplasmic Ca2+-ATPase increases caffeineand halothane-induced contractures in muscle bundles of malignant hyperthermia susceptible and healthy individuals. BMC Anesthesiol 5:8

    PubMed  Google Scholar 

  25. Schuster F, Scholl H, Hager M, Müller R, Roewer N, Anetseder M (2006) The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 102:468–472

    PubMed  CAS  Google Scholar 

  26. The European Malignant Hyperpyrexia Group (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 56:1267–1269

    Google Scholar 

  27. Urwyler A, Deufel Th, McCarthy T, West S for the European Malignant Hyperthermia Group (2001) Guidelines for the detection of malignant hyperthermia susceptibility. Br J Anaesth 86:283–287

    PubMed  CAS  Google Scholar 

  28. Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, Matschke J, Schulte Am Esch J (2001) Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94:95–100

    PubMed  CAS  Google Scholar 

  29. www.emhg.org

Zu 37.4

  1. Annane D, Sébille V, Charpentier C, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871

    PubMed  CAS  Google Scholar 

  2. Bednarik J, Lukas Z, Vondracek P (2003) Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Int Care Med 29:1505–1514

    Google Scholar 

  3. Blobner M, Kochs E, Fink H, et al. (1999) Pharmacokinetics and pharmacodynamics of vecuronium in rats with systemic inflammatory response syndrome: treatment with NGmonomethyl- L-arginine. Anesthesiology 91:999–1005

    PubMed  CAS  Google Scholar 

  4. Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24:1408–1416

    PubMed  CAS  Google Scholar 

  5. Danon MJ and Carpenter S (1991) Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 14:1131–1139

    PubMed  CAS  Google Scholar 

  6. De Jonghe B, Sharshar T, Lefaucheur JP, et al. (2002) Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 288:2859–2867

    PubMed  Google Scholar 

  7. De Letter MACJ, Schmitz PIM, Visser LH, et al. (2001) Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29:2281–2286

    PubMed  Google Scholar 

  8. De Letter MACJ, van Doorn PA, Savelkoul HFJ, et al. (2000) Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 106:206–213

    PubMed  Google Scholar 

  9. Di Giovanni S, Molon A, Broccolini A, et al. (2004) Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55:195–206

    PubMed  Google Scholar 

  10. Fletcher SN, Kennedy DD, Ghosh IR, et al. (2003) Persistent neuromuscular and neurophysiologic abnormalities in longterm survivors of prolonged critical illness. Crit Care Med 31:1012–1016

    PubMed  Google Scholar 

  11. Friedrich O, Hund E, Weber C, et al. (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53–65

    PubMed  CAS  Google Scholar 

  12. Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, et al. (2005) Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 33:349–354

    PubMed  Google Scholar 

  13. Geller TJ, Kaiboriboon K, Fenton GA, et al. (2001) Vecuroniumassociated axonal motor neuropathy: a variant of critical illness polyneuropathy? Neuromuscul Disord 11:579–582

    PubMed  CAS  Google Scholar 

  14. Herridge MS, Cheung AM, Tansey CM, et al. (2003) Oneyear outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348:683–693

    PubMed  Google Scholar 

  15. Hund E (2001) Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248:929–934

    PubMed  CAS  Google Scholar 

  16. Hund E, Fogel W, Krieger D, et al. (1996) Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 24:1328–1333

    PubMed  CAS  Google Scholar 

  17. Hund E, Herkert M, Becker C-M, et al. (1996) A humoral neurotoxic factor in sera of patients with critical illness polyneuropathy (abstr.). Ann Neurol 40:539

    Google Scholar 

  18. Khan J, Harrison TB, Rich MM, et al. (2006) Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 67:1421–1425

    PubMed  Google Scholar 

  19. Latronico N (2003) Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 29:1411–1413

    PubMed  Google Scholar 

  20. Latronico N, Bertolini G, Guarneri B, et al. (2007) Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 11:R11

    PubMed  Google Scholar 

  21. Lewis KS, Rothenberg DM (1999) Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm 56:72–75

    PubMed  CAS  Google Scholar 

  22. Maramattom BV, Wijdicks EFM (2006) Acute neuromuscular weakness in the intensive care unit. Crit Care Med 34:2835–2841

    PubMed  Google Scholar 

  23. Reinhart K, Brunkhorst F, Bone H, et al. (2006) Diagnose und Therapie der Sepsis. S2-Leitlinien der Deutschen Sepsis- Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI). Internist (Berl) 47:356–372

    CAS  Google Scholar 

  24. Rezaiguia-Delclaux S, Lefaucheur JP, Zakkouri M, et al. (2002) Severe acute polyneuropathy complicating orthotopic liver allograft failure. Transplantation 74:880–882

    PubMed  Google Scholar 

  25. Rich MM and Pinter MJ (2003) Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 547(Pt 2):555–566

    PubMed  CAS  Google Scholar 

  26. Schattschneider J, Wasner G, und Baron R (2001) Zytostatikainduzierte Polyneuropathien. Aktuelle Neurologie 28:53–61

    Google Scholar 

  27. Segredo V, Caldwell JE, Matthay MA, et al. (1992) Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 327:524–528

    PubMed  CAS  Google Scholar 

  28. Tennilä A, Salmi T, Pettilä V, et al. (2000) Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 26:1360–1363

    PubMed  Google Scholar 

  29. Van Den Berghe G, Wilmer A, Hermans G, et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–461

    PubMed  Google Scholar 

  30. Van Den Berghe G, Wouters P, Weekers F, et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367

    PubMed  Google Scholar 

  31. Van Den Schaaf M, Beelen A, de Vos R (2004) Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 26:1189–1197

    PubMed  Google Scholar 

  32. Williams S, Horrocks IA, Ouvrier RA, et al. (2007) Critical illness polyneuropathy and myopathy in pediatric intensive care: A review. Pediatr Crit Care Med 8:18–22

    PubMed  Google Scholar 

  33. Zifko UA (2000) Long-term outcome of critical illness polyneuropathy. Muscle Nerve (Suppl 9):S49–S52

    PubMed  CAS  Google Scholar 

  34. Zink W, Kollmar R, Schwab S (2009) Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol 5:372–379

    PubMed  Google Scholar 

Zu 37.5

  1. Abrutyn E, Berlin JA (1991) Intrathecal therapy in tetanus: a meta-analysis. JAMA 266:2262–2267

    PubMed  CAS  Google Scholar 

  2. Ahmadsyah I, Salim A (1985) Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J 291:648–650

    CAS  Google Scholar 

  3. Alpers K, van Treeck U, Frank C (2005) Outbreak of wound botulism in drug useres in Germany, October-December 2005. Euro Surveill 10:E051215.4

    PubMed  Google Scholar 

  4. Anandaciva S, Koray CW (1996) Tetanus and rocuronium in the intensive care unit. Anesthesia 5:879–881

    Google Scholar 

  5. Arnon SS, Schlechter R, Ingelsby TV, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070

    PubMed  CAS  Google Scholar 

  6. Arnon SS (2002) Clinical botulism. In: Brin MF, Hallet M, Jancovic J. Scientific and therapeutic aspects of botulinum toxin. Lipincott Williams, Philadelphia, pp 145–150

    Google Scholar 

  7. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:445–447

    Google Scholar 

  8. Behring E, Kitasato S (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus Immunität bei Thieren. Dtsch Med Wochenschr 16:1027–1049

    Google Scholar 

  9. Bleck TP, Brauner S: Tetanus (1997) In: Scheld WM, Whitley RJ, Durack DT (eds) Infections of the central nervous system, 2nd ed. Lipinscott-Raven, Philladelphia, pp 629–653

    Google Scholar 

  10. Brett MM, Hallas, G, Mpamugo O (2004) Wound botulism in the UK and Ireland. J Med Microbiol 53:555–561

    PubMed  Google Scholar 

  11. Cherington M (1998) Clinical spectrum of botulism. Muscle Nerve 21:701–710

    PubMed  CAS  Google Scholar 

  12. Chertow DS, Tan ET, Maslanka SE, et al. (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296:2476–2479

    PubMed  CAS  Google Scholar 

  13. Coleman EA, Yergler ME (2002) Botulism. Am J Nursing 102:44–47

    Google Scholar 

  14. Domenighetti GM, Savary S, Striker H (1984) Hyperadrenergic syndrome in severe tetanus responsive to labetalol. Br Med J 288:1483–1484

    CAS  Google Scholar 

  15. Duning T, Schabitz WR (2007) Die Behandlung des Tetanus. Nervenarzt. 98:145–155

    Google Scholar 

  16. Farrer JJ, Yen LM, Cook T (2000) Tetanus. J Neurol Neurosurg Psychiatry 332:761–766

    Google Scholar 

  17. Fenicia L, Franciosa G, PourshabanM, et al. (1999) Intestinal toxemia botulism in two young people, caused by Clostridium butyricum Type E. Clin Infect Dis 29:1381–1387

    PubMed  CAS  Google Scholar 

  18. Gupta PS, Kapoor R, Goyal S, et al. (1980) Intrathecal human tetanus immue globulin in early tetanus. Lancet 2:439–440

    PubMed  CAS  Google Scholar 

  19. Meunier FA, Herreros J, Schiavo G, et al. (2002) Molecular mecahnisms of action of botulinal neurotoxins and the synaptic remodelling they induce in vivo at the skeletal neuromuscular junction. In: Massero EJ (ed) Handbook of neurotoxicology, vol I. Humana Press, Totowa, New Jersey, pp 305–347

    Google Scholar 

  20. Merrison AFA, Chidley KE, Dunnett J, Sieradzan KA (2002) Wound botulism associated with subcutaneous drug use. BMJ 325:1020–1022

    PubMed  CAS  Google Scholar 

  21. Mezaki T, Kaji R, Kohara N, et al. (1996) Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 46:845–846

    PubMed  CAS  Google Scholar 

  22. Müller H, Börner U, Ziersky J, et al. (1987) Intrathecal baclofen therapy for tetanus induced spasticity. Anesthesiology 66:76–79

    PubMed  Google Scholar 

  23. Nicolaier A (1884) Über infectiösen Tetanus. Dtsch Med Wochenschr 10:842–844

    Google Scholar 

  24. Passaro DJ, Werner SB, McGee J, et al. (1998) Wound botulism associated with black tar heroin among injecting drug users. JAMA 279:859–863

    PubMed  CAS  Google Scholar 

  25. Salmaso S (1999) Special issue on botulism. European communicable disease bulletin 4:1–16

    Google Scholar 

  26. Schiavo G, Rosetto O, Tonello F, et al. (1995) Intracellular targets and metalloprotease activity of tetanus and botulinum toxin neurotoxins. Curr Top Microbiol Immunol 195:257–274

    PubMed  CAS  Google Scholar 

  27. Schmidt RD, Schmidt TW (1992) Infant botulism: a case series and review of the literature. J Emerg Med 10:763–772

    Google Scholar 

  28. Thwaites CL (2002) Tetanus. Practical Neurology 2:130–137

    Google Scholar 

  29. Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K, Soni N, White NJ, Farrar JJ (2006) Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 368(9545):1398–1389

    Google Scholar 

Zu 37.6

  1. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548–54

    PubMed  CAS  Google Scholar 

  2. Baek WS, Bashey A, Sheean GL (2007) Complete remission induced by rituximab in refractory, seronegative, musclespecific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatr 78:771–772

    PubMed  Google Scholar 

  3. Chan A, Lee DH, Linker R, et al. (2007) Rescue therapy with anti- CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254:1604–1606

    PubMed  Google Scholar 

  4. Gajdos P et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 62:1689–1693

    PubMed  Google Scholar 

  5. Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008:CD002277

    Google Scholar 

  6. Gold R, Toyka KV (2007) Immuntherapie neurologischer Erkrankungen, 2.Aufl. Uni-Med, Bremen

    Google Scholar 

  7. Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530–535

    PubMed  CAS  Google Scholar 

  8. Harper CM (1999) Electrodiagnosis of end plate disease. In: Engel AG (ed) Myasthenia gravis and Myasthenic Disorders. Oxford University Press, Oxford, pp 65–84

    Google Scholar 

  9. Jarius S, Eichhorn P, Albert MH, et al. (2007) Intravenous immunoglobulins contain naturally occurring antibodies that mimic cytoplasmatic antibodies and activate neutrophils in a TNF-alpha dependant and Fc-receptor independant way. Blood 109:4376–4382

    PubMed  CAS  Google Scholar 

  10. Liu JF, Wang WX, Xue J, et al. (2010) Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 14:153–160

    PubMed  Google Scholar 

  11. Maselli RA, Ellis W, Mandler RN (1997) Cluster of wound botulism in california: clinical, electrophysiologic, and pathologic study. Muscle Nerve 20:1284–1295

    PubMed  CAS  Google Scholar 

  12. Müllges W, Toyka KV (1997) Akute Muskelschwäche – Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 34:110–23

    Google Scholar 

  13. Müllges W, Gold R, Toyka KV (2003) Myasthene Krise. Intensivmedizin und Notfallmedizin 40:111–123

    Google Scholar 

  14. Müllges W, Stoll G (2009) Intensivmedizinische Probleme bei neuromuskulärern Krankheiten. Intensivmed up2date 5:209–228

    Google Scholar 

  15. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y (2005) Efficiacy of low-dose FK506 in the treatment of myasthenia gravis – a randomized pilot study. Eur Neurol 53:146–150

    PubMed  CAS  Google Scholar 

  16. Oosterhuis HJGH (1989) The natural course of myasthenia gravis. J Neurol Neurosurg Psychiatr 52:1121–1127

    PubMed  CAS  Google Scholar 

  17. Pascuzzi RM (2001) Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. Semin Neurol 21:425–440

    PubMed  CAS  Google Scholar 

  18. Quereshi AI, Choudry MA, Akbar MS, et al. (1999) Plasma exchange versus immunoglobulin treatment in myasthenic crisis. Neurology 52:629–632

    Google Scholar 

  19. Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in lambert-eaton myasthenic syndrome. Neurology 54:603–607

    PubMed  CAS  Google Scholar 

  20. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev CD 002828

    Google Scholar 

  21. Seneviratne J, Mandrekar J, Wijdicks EFM, Rabinstein AA (2008) Noninvasive ventilation in myasthenic crisis. Arch Neurol 65:54–58

    PubMed  Google Scholar 

  22. Smith AG, Wald J (1996) Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 46:1143–1145

    PubMed  CAS  Google Scholar 

  23. Thomas CE, Mayer SA, Gungor Y, et al. (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260

    PubMed  CAS  Google Scholar 

  24. Vincent A, Drachman B (2002) Myasthenia gravis. Adv Neurol 88:159–188

    PubMed  CAS  Google Scholar 

  25. Tindall RS (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719–724

    PubMed  CAS  Google Scholar 

  26. Toyka KV, Gold R, Hohlfeld R, et al. (2008) Myasthenia gravis. In: Diener HC, Putzki N (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 4. Aufl. Thieme, Stuttgart, S 686–703

    Google Scholar 

  27. Vincent A, Drachman B (2002) Myasthenia gravis. Adv Neurol 88:159–188

    PubMed  CAS  Google Scholar 

  28. Wu JY, Kuo PH, Fan PC, et al. (2009) The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care 10:35–42

    PubMed  Google Scholar 

  29. Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander- Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Prof. Dr. Stefan Schwab

  2. Benediktuskrankenhaus, Neurologische Klinik und Geriatrie Johannes Wesling Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden

    Prof. Dr. Peter Schellinger

  3. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Prof. Dr. Christian Werner

  4. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Prof. Dr. Andreas Unterberg & Prof. Dr. Dr. Werner Hacke

Authors
  1. Prof. Dr. Stefan Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Peter Schellinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Christian Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. Andreas Unterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. Dr. Werner Hacke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Stefan Schwab

  2. Benediktuskrankenhaus, Neurologische Klinik und Geriatrie Johannes Wesling Klinikum Minden, Hans-Nolte-Str. 1, 32429, Minden

    Peter Schellinger

  3. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Christian Werner

  4. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Andreas Unterberg  & Werner Hacke  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (2012). Neuromuskuläre Erkrankungen. In: Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (eds) NeuroIntensiv. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16911-3_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-16911-3_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-16910-6

  • Online ISBN: 978-3-642-16911-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation